Market Access News | pharmaphorum

News

J&J bags first FDA approval for a GPRC5D drug

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat

News

Novavax swings to profit as it preps new COVID jab launch

Just a few months after suggesting it may not survive to the end of 2023, Novavax has posted improved finances and a second-quarter profit, as it readies the launch of an

News

Sage considering cuts after FDA setback

Sage Therapeutics is facing the possibility of job losses and other cutbacks in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the

News

Astellas' Iveric takeover rewarded with FDA nod for GA drug

The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company

News

Zuranolone cleared for post-partum depression, but not MDD

Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ

News

AZ, Sanofi's Beyfortus gets CDC okay for RSV prevention

The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centre

J&J bags first FDA approval for a GPRC5D drug

Novavax swings to profit as it preps new COVID jab launch

Sage considering cuts after FDA setback

Astellas' Iveric takeover rewarded with FDA nod for GA drug

Zuranolone cleared for post-partum depression, but not MDD

AZ, Sanofi's Beyfortus gets CDC okay for RSV prevention

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks